Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2025-10-01 00:00:00 ET · period of report 2025-09-29 · accession 0001867899-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-01 | 2025-09-29 | KNSA | Tessari Eben | COO | S - Sale+OE | $38.33 | -42.0K | 34.6K | -55% | -$1.61M |
| D | 2025-10-01 | 2025-09-29 | KNSA | Tessari Eben | COO | M - OptEx | $17.92 | +42.0K | 76.6K | +122% | +$752.6K |
| D | 2025-10-01 | 2025-09-29 | KNSA | Tessari Eben | COO | M - OptEx | $0.00 | -42.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2025-09-29 | S | D | 42,000 | $38.33 | 34,552 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $37.92 and $38.85. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 2 | Common | Class A Ordinary Share | 2025-09-29 | M | A | 42,000 | $17.92 | 76,552 | D | — | — | |
| 3 | Derivative | Share Option | 2025-09-29 | M | D | 42,000 | $0.00 | 0 | D | $17.92 · — to 2029-03-03 | 42,000 Class A Ordinary Share | (F3) The option is fully vested and exercisable. |